Directors

Dr. Liu Zhong Yi

Chairman of the Board and Founder of Lotus Pharmaceuticals, Inc. in the United States and its Chinese antecedent, Liang Fang Pharmaceuticals Co., Ltd. in Beijing. He earned his Master’s Degree in Beijing hospitals, after doing his undergraduate studies in his homeland of Inner Mongolia. Dr. Liu holds the title of Deputy Chief Physician, as a professional apothecary, in operating Lotus (Liang Fang) as one of China’s most innovative and fastest growing pharmaceutical companies. As a researcher and medical student, Dr. Liu excelled in the development of many new drugs in wide use in China today. While working for the Chinese Government in 1992, he established the Research Center of Space Flight Biological Engineering Technology, and continued his renowned research related to incretion diseases. Four years later, entering the private sector and invigorated by burgeoning capitalism in China, Dr. Liu started his first pharmaceutical company in Beijing.

Dr. Ian Ashley

Director on the founding Lotus Board of Directors. Dr. Ashley graduated Summa Cum Laude with degrees in Chemistry and Biochemistry from Oberlin College before graduating from Baylor College of Medicine in Houston, Texas in 1996. Previously he worked for Merck & Co. in Research and Development with focus on hypertension and calcium channel blockers. He is ABEM Board Certified in Emergency Medicine after finishing a residency in Emergency Medicine at Loma Linda University Medical Center in Southern California. He currently serves as Attending Physician at Providence Hospital in Waco, Texas.

Li Ping

Director on the founding Lotus Board of Directors. Mr. Ping graduated from the Beijing Medical School, apothecary; served as salesman and deputy manager of the sales department of Beijing Dongcheng Medicine Wholesale Company in 1984-1999; served as director of Lotus Pharmaceuticals responsible for medicine and clinic promotions since the year of 2000.

Liu Jin

Director on the founding Lotus Board of Directors. Mr. Liu graduated from the Middling Finance School of Wulanchabu City of Inner Mongolia in 1958, senior accountant; served as accountant for Finance Bureau of Liangcheng County, 1958-1970; served as accountant and accountant general for Finance Bureau of Chayouqiqnqi of Inner Mongolia; served as director of Lotus Pharmaceuticals being responsible for finance since the year of 2000.

Mel Rothberg

Director on the founding Lotus Board of Directors. Mr. Rothberg has, over the last 30 years, participated in the development of the South Florida bioscience industry and is presently Chairman of Bioflorida’s South Florida Bioscience Consortium. He has held executive positions in the medical device, information technology and biopharmaceutical sectors. Currently he is Chairman and CEO of Advanced Processing and Imaging, CEO of Dharma Biomedical and CEO of Rothberg Associates, Inc. Previously he was Executive Vice President, Operations of Viragen Inc., Plantation, Florida (VRA: AMEX) and Director of Viragen International Inc. (VGNI: OTCBB) and Viranative AB (Sweden), where he was responsible for manufacturing, regulatory, business development, marketing and sales of Viragen’s lead drug, Multiferon. Prior to Viragen, Mr. Rothberg was Vice President of Manufacturing and Business Development for Althin Medical a Swedish publicly traded company focused on the hemodialysis machine and disposables market. He previously held multiple roles with Dow Chemical and Cordis Dow and was instrumental in selling Dow’s dialysis division to Althin Medical. He held both international and domestic positions within Dow’s subsidiary CD Medical including responsibility for offices in Australia, Singapore and Japan and was Managing Director of Cordis Dow’s European manufacturing operations located in the Netherlands. Mr. Rothberg presently resides in South Florida in the United States.

Song Guoan

Director on the founding Lotus Board of Directors. Mr. Song graduated from Shenyang Industry School in 1957, Senior Engineer; served as technical worker, technician, director of workshop and deputy factory director of Shenyang pharmaceuticals factory during the years of 1957-1977; served as engineer and engineer general of Spaceflight Industry Company during the years of 1978-1999; served as director of Lotus Pharmaceuticals responsible for production since the year of 2000.

Caeli W. Widger

Director on the founding Lotus Board of Directors. From her Manhattan office, Mrs. Widger directs large-scale staffing projects, ranging from sales force expansion to executive searches, for young technology companies on both coasts of the U.S. She's currently managing a talent search for Mimeo.com (www.mimeo.com), an international print-on-demand solutions provider named one of America's fastest-growing technology companies by Red Herring and the Deloitte Fast 50 List. She holds a BA from Wellesley College, an MFA from the University of Montana, and co-directs The Sackett School, a renown creative writing institute in New York City (www.sackettworkshop.com). Mrs. Widger now resides in Brooklyn, New York, having previously lived in San Francisco and London.

Xian Wenli

Director on the founding Lotus Board of Directors. Ms. Xian graduated from Western China Medical University with a Bachelor’s Degree, served as staff physician , attending physician and deputy chief physician in 731 Hospital of Spaceflight Ministry; served as director and Vice President of Lotus Pharmaceuticals responsible for product quality since the year of 2000.

This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses.